Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CPT1A | P50416 | 15/20 | 0.54 |
| ▸ | CPT2 | P23786 | 6/20 | 0.54 |
| ▸ | CPT1B | Q92523 | 13/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999963 | 0.90 | CYP2C9 (0.56) | CYP2C9CPT1ACPT2CPT1B | |
| SCHEMBL4055322 | 0.90 | CYP2C9 (0.56) | CYP2C9CPT1ACPT2CPT1BSMN1; SMN2 | |
| SCHEMBL12567437 | 0.81 | CNR1 (0.54) | CPT1ACPT2CPT1BSMN1; SMN2MAPT | |
| SCHEMBL1998991 | 0.80 | CYP2C9 (0.55) | CYP2C9CPT1ACPT2CPT1BSMN1; SMN2 | |
| SCHEMBL2001755 | 0.75 | RORC (0.55) | CYP2C9CPT1A | |
| SCHEMBL18581887 | 0.74 | CYP2C9 (0.66) | CYP2C9CPT1ACPT2CPT1BSMN1; SMN2 | |
| SCHEMBL18581858 | 0.74 | CPT1A (0.62) | CYP2C9CPT1ACPT2CPT1BSMN1; SMN2 | |
| SCHEMBL5021967 | 0.72 | CPT1A (0.60) | CYP2C9CPT1ACPT2CPT1BMAPT | |
| SCHEMBL28796755 | 0.72 | CPT1A (0.74) | CPT1ACPT2CPT1BSMN1; SMN2MAPT | |
| SCHEMBL5021974 | 0.72 | CPT1A (0.56) | CYP2C9CPT1ACPT2CPT1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2009035997-A2 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CNR1, CNR2, TRPV1 | CYP2C9 210/4885CPT1A 1957/4885CPT2 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.